Search results for "peptidase"

showing 10 items of 567 documents

Increased pain and neurogenic inflammation in mice deficient of neutral endopeptidase

2009

The complex regional pain syndrome (CRPS) is characterized by enhanced neurogenic inflammation, mediated by neuropeptides. Neutral endopeptidase (NEP) is a key enzyme in neuropeptide catabolism. We used NEP knock out (ko) mice to investigate whether NEP deficiency leads to increased pain behavior and signs of neurogenic inflammation after soft tissue trauma with and without nerve injury. After chronic constriction injury (CCI) of the right sciatic nerve, NEP ko mice were more sensitive to heat, to mechanical stimuli, and to cold than wild type mice. Tissue injury without nerve injury produced no differences between genotypes. After CCI, NEP ko mice showed increased hind paw edema but lower …

medicine.medical_specialtyHot TemperaturePainSubstance PEnzyme-Linked Immunosorbent AssayCalcitonin gene-related peptideSubstance PEndothelin 1lcsh:RC321-571chemistry.chemical_compoundMiceCGRP catabolismEdemaInternal medicinePhysical StimulationMedicineAnimalsEdemaMuscle SkeletalNeprilysinlcsh:Neurosciences. Biological psychiatry. NeuropsychiatryPain MeasurementSkinMice KnockoutNeurogenic inflammationEndothelin-1business.industryCCIfungiNerve injurymedicine.diseaseNeutral endopeptidaseEndothelin 1Sciatic NerveHindlimbCold TemperatureMice Inbred C57BLComplex regional pain syndromeEndocrinologyNeurologychemistryAnesthesiaNeprilysinmedicine.symptomNeurogenic InflammationbusinessSkin TemperaturePrimarily cold CRPSNeurobiology of Disease
researchProduct

Incretin-Based Therapies, Glucometabolic Health and Endovascular Inflammation

2013

Incretin peptides are a group of gastrointestinal hormones that play a prominent role in the regulation of glucose metabolism. Incretin-based therapies (IBTs) have recently emerged as an important treatment option for patients with type 2 diabetes mellitus (T2DM). These pharmaceutical agents may be specially well suited for patients who are overweight or obese with primarily post-meal glucose peaks, and in whom traditional first-line oral agents have failed to maintain adequate glycemic control. There are 2 classes of IBTs: the dipeptidyl peptidase-4 (DPP-4) inhibitors and the glucagon-like peptide 1 (GLP-1) receptor agonists. The ultimate effect of both types of agents is to augment GLP-1 …

medicine.medical_specialtyLipoproteinsIncretin type 2 diabetes mellitus metabolic syndrome lipoproteinsIncretinBiologyIncretinsGlucagon-Like Peptide-1 ReceptorWeight lossDiabetes mellitusInternal medicineDrug DiscoverymedicineAnimalsHumansGlucose homeostasisAdiponectin secretionLipoproteinInflammationPharmacologyDipeptidyl-Peptidase IV InhibitorsDrug Discovery3003 Pharmaceutical ScienceMedicine (all)digestive oral and skin physiologyGlucagon secretionType 2 Diabetes MellitusIncretinAtherosclerosismedicine.diseaseMetabolic syndromeType 2 diabetes mellituGlucoseEndocrinologyDiabetes Mellitus Type 2Metabolic syndromemedicine.symptomCurrent Pharmaceutical Design
researchProduct

Nutrition and physical activity: French intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCE…

2021

International audience; This document is a summary of the French intergroup guidelines regarding the nutrition and physical activity (PA) management in digestive oncology. This collaborative work was produced under the auspices of all French medical and surgical societies involved in digestive oncology, nutrition and supportive care. It is based on published guidelines, recent literature review and expert opinions. Recommendations are graded according to the level of evidence. Malnutrition affects more than half of patients with digestive cancers and is often underdiagnosed. It has multiple negative consequences on survival, quality of life and risk of treatment complications. Consequently,…

medicine.medical_specialtyMedicine (miscellaneous)[SDV.CAN]Life Sciences [q-bio]/CancerContext (language use)symptoms and symptom managementDiseasegastrointestinal (lower)03 medical and health sciences0302 clinical medicineQuality of life (healthcare)[SDV.CAN] Life Sciences [q-bio]/CancerEndopeptidasesmedicineHumans030212 general & internal medicineStage (cooking)Intensive care medicineExerciseSocieties MedicalOncology (nursing)business.industryCancerGeneral MedicinePerioperativeEvidence-based medicinemedicine.diseasegastrointestinal (upper)3. Good healthsupportive careMedical–Surgical NursingMalnutritionpancreatic030220 oncology & carcinogenesisQuality of Lifebusinesseducation and trainingFollow-Up StudiesBMJ Supportive & Palliative Care
researchProduct

The deubiquitinating enzyme CYLD regulates the differentiation and maturation of thymic medullary epithelial cells.

2014

The cross talk between thymocytes and the thymic epithelium is critical for T-cell development and the establishment of central tolerance. Medullary thymic epithelial cells (mTECs) are located in the thymic medulla and mediate the elimination of self-reactive thymocytes, thereby preventing the onset of autoimmunity. Previous studies identified the deubiquitinating enzyme CYLD as a critical regulator of T-cell development by activating proximal T-cell receptor signaling during the transition of double-positive to single-positive thymocytes. Here we evaluated the impact of the naturally occurring short-splice variant of the cyld gene (sCYLD) on the development and maturation of mTECs. We foun…

medicine.medical_specialtyMedullary cavityImmunologyReceptors Antigen T-CellCell CountThymus GlandBiologyDeubiquitinating Enzyme CYLDImmunophenotypingMiceInternal medicinemedicineImmunology and AllergyAnimalsMice KnockoutThymocytesUbiquitinationCell DifferentiationEpithelial CellsCell BiologyCell biologyDeubiquitinating Enzyme CYLDCysteine EndopeptidasesEndocrinologyPhenotypeAntigens SurfaceMutationFemaleSignal TransductionImmunology and cell biology
researchProduct

Clinical and genetic characteristics of 21 Spanish patients with biallelic pathogenic SPG7 mutations.

2021

Spastic paraplegia type 7 (SPG7) is one of the most common hereditary spastic paraplegias. SPG7 mutations most often lead to spastic paraparesis (HSP) and/or hereditary cerebellar ataxia (HCA), frequently with mixed phenotypes. We sought to clinically and genetically characterize a Spanish cohort of SPG7 patients. Patients were recruited from our HCA and HSP cohorts. We identified twenty-one patients with biallelic pathogenic SPG7 mutations. Mean age at onset was 37.4 years (SD ± 14.3). The most frequent phenotype was spastic ataxia (57%), followed by pure spastic paraplegia (19%) and complex phenotypes (19%). Isolated patients presented with focal or multifocal dystonia, subclinical myopat…

medicine.medical_specialtyNeurogeneticsCompound heterozygosityGastroenterologyInternal medicinemedicineSpasticHumansMyopathySubclinical infectionDystoniaCerebellar ataxiabusiness.industrySpastic Paraplegia HereditaryMetalloendopeptidasesmedicine.diseasenervous system diseasesOptic AtrophyPhenotypeNeurologyMutationATPases Associated with Diverse Cellular ActivitiesNeurology (clinical)medicine.symptombusinessSpastic paraplegia type 7Journal of the neurological sciences
researchProduct

Expression pattern of matrix metalloproteinases-2 and -9 and their tissue inhibitors in patients with chronic inflammatory demyelinating polyneuropat…

2021

Background: Matrix metalloproteinases (MMPs) are a heterogeneous family of endopeptidases that play a role in many physiological functions, including the immune response. An imbalance between the activity of MMPs and their physiological tissue inhibitors (TIMPs) has been proposed in the pathophysiology of different autoimmune disorders. We aimed to assess the plasmatic levels of MMP-2, MMP-9, and their inhibitors TIMP-1 and -2 in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Subjects and methods: Twenty patients with CIDP and 20 age- and sex-matched healthy controls were enrolled. Plasma concentrations of MMP-2, MMP-9, TIMP-1, and TIMP-2 were determined by the enzy…

medicine.medical_specialtyNeurologyChronic inflammatory demyelinating polyneuropathyCIDPDermatologyMatrix metalloproteinaseGastroenterologyTissue inhibitor of matrix metalloproteinase03 medical and health sciences0302 clinical medicineImmune systemExpression patternDownregulation and upregulationInternal medicineEndopeptidasesmedicineTIMPHumansIn patient030212 general & internal medicineMMPbusiness.industryGeneral Medicinemedicine.diseaseMatrix MetalloproteinasesPathophysiologyMatrix metalloproteinasePsychiatry and Mental healthMatrix Metalloproteinase 9Polyradiculoneuropathy Chronic Inflammatory DemyelinatingMatrix Metalloproteinase 2Settore MED/26 - NeurologiaNeurology (clinical)business030217 neurology & neurosurgeryNeurological Sciences
researchProduct

Substance P Serum Degradation in Complex Regional Pain Syndrome – Another Piece of the Puzzle?

2021

In a previous study, we demonstrated that the serum peptidase system might be less efficient in complex regional pain syndrome (CRPS). Since the neuropeptide substanc P (SP) contributes to inflammation in CRPS, we now investigated the metabolism of SP in CRPS specifically. An SP metabolism assay was performed in 24 CRPS patients, which constitute a subgroup of our previous investigation on BK degradation. In addition, we included 26 healthy controls (24 newly recruited plus 2 from our previous investigation), and 13 patients after limb trauma, who did not fulfil the CRPS diagnostic criteria (trauma controls, TC) were included. We adapted a thin layer chromatography assay (TLC) to quantify S…

medicine.medical_specialtyNeuropeptideBradykininInflammationSubstance PPeptidyl-Dipeptidase ASubstance PBradykininchemistry.chemical_compoundInternal medicinemedicineHumansNeprilysinbiologybusiness.industryAngiotensin-converting enzymemedicine.diseaseAnesthesiology and Pain MedicineEndocrinologyComplex regional pain syndromeNeurologychemistrybiology.proteinNeurology (clinical)medicine.symptombusinessComplex Regional Pain SyndromesEx vivoPeptide HydrolasesThe Journal of Pain
researchProduct

Increased mRNAs for procollagens and key regulating enzymes in rat skeletal muscle following downhill running.

1999

The purpose of the study was to investigate pre-translational regulation of collagen expression after a single bout of exercise. We analysed steady-state messenger ribonucleic acid (mRNA) levels for collagen types I, III and IV, alpha- and beta-subunits of prolyl 4-hydroxylase and lysyl oxidase (enzymes modifying procollagen chains), and enzyme activity of prolyl 4-hydroxylase from rat soleus muscle (MS) and the red parts of quadriceps femoris muscle (MQF) after 12 h and after 1, 2, 4, 7 and 14 days of downhill (-13.5 degrees ) treadmill running at a speed of 17 m.min-1 for 130 min. Histological and biochemical assays revealed exercise-induced muscle damage in MQF but not MS. Steady-state m…

medicine.medical_specialtyPhysiologyClinical BiochemistryPhysical ExertionProcollagen-Proline DioxygenaseLysyl oxidaseBiologyRunningProtein-Lysine 6-OxidaseHydroxyprolinechemistry.chemical_compoundType IV collagenPhysiology (medical)Internal medicineGene expressionmedicineAnimalsExertionRNA MessengerRats WistarMuscle SkeletalGlucuronidaseSoleus muscleSkeletal muscleBlotting NorthernRatsProcollagen peptidaseEndocrinologymedicine.anatomical_structurechemistryFemaleCollagenProcollagenPflugers Archiv : European journal of physiology
researchProduct

Critical role of dipeptidyl peptidase IV in neuropeptide Y-mediated endothelial cell migration in response to wounding

2001

Recently, we have discovered that neuropeptide Y (NPY), a sympathetic neurotransmitter, is also present in human umbilical endothelial cells (HUVECs), and is potently chemotactic and angiogenic by acting on one or several of Y1-Y5 receptors. In HUVECs, NPY is co-localized with dipeptidyl peptidase IV (DPPIV) which cleaves Tyr(1)-Pro(2) from NPY(1-36) to form NPY(3-36) resulting in the formation of a non-Y1 receptor agonist, which remains angiogenic. Presently we studied the effects of DPPIV's blockade using monoclonal antibodies (mAbs) on migration of HUVECs in response to NPY(1-36) or NPY(3-36) following cell wounding. Both peptides caused similar dose-dependent increases in cell migration…

medicine.medical_specialtyTime FactorsEndotheliumPhysiologyDipeptidyl Peptidase 4Blotting WesternImmunoblottingBiologyBiochemistryDipeptidyl peptidaseUmbilical CordCellular and Molecular NeuroscienceEndocrinologyWestern blotCell MovementInternal medicinemental disordersmedicineHumansNeuropeptide YReceptormedicine.diagnostic_testChemotaxisNeuropeptide Y receptorhumanitiesCell biologyBlotEndothelial stem cellEndocrinologymedicine.anatomical_structureWounds and InjuriesEndothelium VascularPeptides
researchProduct

Liver specific deletion of CYLDexon7/8 induces severe biliary damage, fibrosis and increases hepatocarcinogenesis in mice

2012

Background & Aims CYLD is a tumor suppressor gene that is mutated in familial cylindromatosis, an autosomal dominant predisposition to tumors of skin appendages. Reduced CYLD expression has been observed in other tumor entities, including hepatocellular carcinoma. In the present study, we analyzed the role of CYLD in liver homeostasis and hepatocarcinogenesis in vivo . Methods Mice with liver-specific deletion of CYLDexon7/8 ( CYLD FF xAlbCre ) were generated. Liver tissues were histologically analyzed and oval cell activation was investigated. Hepatocarcinogenesis was induced by diethylnitrosamine/phenobarbital (DEN/PB). Microarray expression profiling of livers was performed in untreated …

medicine.medical_specialtyTumor suppressor geneBiliary Tract DiseasesIn Vitro TechniquesBiologymedicine.disease_causeDimethylnitrosamineDeubiquitinating Enzyme CYLDMiceRisk FactorsFibrosisInternal medicinemedicineAnimalsHomeostasisGenetic Predisposition to DiseaseHepatologyLiver NeoplasmsExonsTransforming growth factor betamedicine.diseaseFibrosisMice Mutant StrainsDeubiquitinating Enzyme CYLDMice Inbred C57BLGene expression profilingCysteine EndopeptidasesDisease Models AnimalPhenotypeEndocrinologyLiverPhenobarbitalHepatocellular carcinomaCancer researchbiology.proteinCell activationCarcinogenesisGene DeletionJournal of Hepatology
researchProduct